Anti cd3 plus anti cd28 antibodies

Manufactured by BioLegend

Sourced in United States

Anti-CD3 plus anti-CD28 antibodies are a laboratory reagent used to activate T cells. The antibodies bind to specific cell surface proteins, CD3 and CD28, to provide the necessary signals for T cell activation and proliferation.

Automatically generated - may contain errors

Lab products found in correlation

Immunomagnetic system, by Miltenyi Biotec (1 mentions) Anti cd3 antibody, by BioLegend (1 mentions) Carboxyfluorescein succinimidyl ester (cfse), by Thermo Fisher Scientific (1 mentions) Pan t labeling system, by AllCells (1 mentions) 3h thymidine, by PerkinElmer (1 mentions) Ficoll density separation, by GE Healthcare (1 mentions) Cd45ro apc, by BioLegend (1 mentions) Facscanto 2, by BD (1 mentions) Cd8 apc, by BioLegend (1 mentions) Cd3 fitc, by BioLegend (1 mentions) Cd4 pe, by BioLegend (1 mentions) Cd45ra pe, by BioLegend (1 mentions) Cd56 apc, by BioLegend (1 mentions) Phytohemagglutinin (pha), by Merck Group (1 mentions)

Spelling variants of this product

Anti-CD3 (468 citations) Anti-CD28 (244 citations) Anti-CD3/CD28 antibodies (11 citations) Anti-CD3/CD28 (8 citations) Anti-CD3/anti-CD28 antibodies (6 citations) CD3/CD28 antibodies (3 citations) CD3 antibodies (2 citations)

2 protocols using anti cd3 plus anti cd28 antibodies

T Cell Proliferation Assay with TAPBPL-Ig

Check if the same lab product or an alternative is used in the 5 most similar protocols

Normal human peripheral blood CD3⁺ Pan T cells that were negatively isolated from mononuclear cells using an indirect immunomagnetic Pan‐T labeling system were purchased from ALLCELLS, LLC (Alameda, CA). Murine CD3⁺ T cells were purified from C57BL/6 mice by an immunomagnetic system (Miltenyi, Auburn, CA), and the purity of the cells was usually > 95%. T cells were stimulated with anti‐CD3 antibody, or anti‐CD3 plus anti‐CD28 antibodies (BioLegend) in the presence of TAPBPL‐Ig or control Ig for 3 days. Proliferative response was assessed by pulsing the culture with 1 µCi of [³H] thymidine (PerkinElmer, Inc., Downers Grove, IL) 12 h before harvest. Incorporation of [³H] thymidine was measured by liquid scintillation spectroscopy (PerkinElmer, Inc.). For CFSE assay, splenocytes were labeled with CFSE (Thermo Fisher Scientific) and stimulated with anti‐CD3 antibody in the presence of TAPBPL‐Ig or control Ig. The cells were analyzed by flow cytometry.

Lin Y., Cui C., Su M., Silbart L.K., Liu H., Zhao J., He L., Huang Y., Xu D., Wei X., Du Q, & Lai L. (2021). Identification of TAPBPL as a novel negative regulator of T‐cell function. EMBO Molecular Medicine, 13(5), e13404.

+ Open protocol

+ Expand

Evaluation of Lymphocyte Subsets and Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll density separation (GE healthcare, Life Systems). For the evaluation of different lymphocyte subsets, PBMCs were stained with the following fluorochrome-conjugated monoclonal antibodies against the following cell surface markers: CD3 FITC (Biolegend, clone OKT3), CD4 PE (Biolegend, clone OKT4), CD8 APC (Biolegend, clone SK1), CD19 PerCP-Cy5 (Biolegend, clone 4G7), CD56 APC (Biolegend, clone 5.1H11), CD45 RA PE (Biolegend, clone HI100), and CD45 RO APC (Biolegend, clone UCHL1). For proliferation assays, PBMCs were stained with CellTracker™ green CMDFA dye (ThermoFisher Scientific, USA). Cells were stimulated with purified anti-CD3 plus anti-CD28 antibodies (BioLegend, USA) or PHA (Sigma) for 5 days at 37 °C 5% CO₂. Before sample acquisition, PBMCs were stained using the murine PE-conjugated monoclonal antibody against human CD3 (Biolegend, clone OKT3). All samples were acquired on FACSCanto II (BD bioscience) and analyzed with the use of FlowJo 7.6.5 software (Tree Star, Ashland, OR).

Lugo-Reyes S.O., Pastor N., González-Serrano E., Yamazaki-Nakashimada M.A., Scheffler-Mendoza S., Berron-Ruiz L., Wakida G., Nuñez-Nuñez M.E., Macias-Robles A.P., Staines-Boone A.T., Venegas-Montoya E., Alaez-Verson C., Molina-Garay C., Flores-Lagunes L.L., Carrillo-Sanchez K., Niemela J., Rosenzweig S.D., Gaytan P., Yañez J.A., Martinez-Duncker I., Notarangelo L.D., Espinosa-Padilla S, & Cruz-Munoz M.E. (2021). Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations. Journal of clinical immunology, 41(6), 1291-1302.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!